Aquestive Gets $10.0 Million Upfront From Eton For Libervant Rights, Keeps Manufacturing For 20 Years
The license adds up to $47.5 million in milestones and mid-teens royalties, with launch targeted for April 2027 pending final FDA approval.
Aquestive Therapeutics received a $10.0 million upfront fee from Eton Pharmaceuticals for exclusive U.S. rights to its Libervant seizure-rescue film, according to an 8-K filed Wednesday. The license agreement was signed Tuesday, and Aquestive stays on as the product's exclusive manufacturer.
What the 8-K says
Aquestive can earn up to $47.5 million more in regulatory and commercial milestones. The filing lists $10.0 million at first U.S. commercial sale, reduced to $5.0 million if full FDA approval for ages 2–5 has not been received.
It also lists $2.5 million on FDA approval for ages 6–11, and up to $35.0 million tied to annual U.S. net sales levels. On top of that, Aquestive will receive royalties on annual net sales at a mid-teens percentage rate.
A separate supply agreement makes Aquestive the exclusive manufacturer and supplier to Eton, subject to specified exceptions. Its initial term is 20 years, then it renews automatically for three-year periods unless either side gives notice at least two years before a term ends.
Regulatory status and launch timing
Per the company release, Libervant has only tentative FDA approval, covering patients 2 to 5 and 12 and older. Eligibility for full approval at ages 12 and up is expected after Valtoco's orphan drug exclusivity expires on January 10, 2027.
A separate application to add ages 6 to 11 has an FDA target action date of March 29, 2027. Eton anticipates an April 2027 launch, subject to final FDA approval.
The release puts the U.S. seizure rescue market above $450 million annually. Third-party research cited in it found that 71% of 101 surveyed patients preferred film to 13% for nasal spray, assuming equal efficacy. The release says that reflects stated preferences, not comparative clinical outcomes.
What it changes
Aquestive trades control of U.S. sales for upfront cash, milestone payments and royalties, while keeping the manufacturing role. Most of the milestone money depends on FDA approvals and on sales levels that Eton's selling must reach, and the release says royalties depend on net sales.
The release also lists Eton's right to terminate the license among the risks. Aquestive CEO Daniel Barber said Eton's focus on specialty medicines and patient access "will be essential" to making Libervant available.
The next dated marker is the FDA's March 29, 2027 target date for the ages 6 to 11 application, ahead of Eton's anticipated April 2027 launch.
Sources
- 8-K Filing — Aquestive Therapeutics, Inc. (AQST) — SEC EDGAR
- Exhibit etonaquestivelibervantpr.htm — Aquestive Therapeutics, Inc. 8-K exhibit — SEC EDGAR